Significant correlation between chromosomal aberration and nuclear morphology in urothelial carcinoma

Acta Histochemica et Cytochemica

Volumn 45, Issue 1, 2012, Pages 25-33

  Shuto, Masayo ^a   Seyama, Atsushi ^a   Gotoh, Yoshiya ^a   Kamada, Kouichi ^a   Nakamura, Masaru ^a   Warigaya, Kenji ^b   Watanabe, Hiroshi ^a   Ueno, Munehisa ^a   Shimizu, Michio ^a   Fukuda, Toshio ^c   Murata, Shin Ichi ^a,b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY   (Japan)

Author keywords

Chromosome; Nuclear morphology; Urinary bladder; Urothelial carcinoma; UroVysion

Indexed keywords

EID: 84857837923     PISSN: 00445991     EISSN: 13475800     Source Type: Journal    
DOI: 10.1267/ahc.11048     Document Type: Article

References (45)

1. Baffa, R., Letko, J., McClung, C., LeNoir, J., Vecchione, A. and Gomella, L. G. (2006) Molecular genetics of bladder cancer: targets for diagnosis and therapy. J. Exp. Clin. Cancer Res. 25; 145-160.
2. Berggren de Verdier, P. J., Kumar, R., Adolfsson, J., Larsson, P., Norming, U., Onelov, E., Wijkstrom, H., Steineck, G. and Hemminki, K. (2006) Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer. Scand. J. Urol. Nephrol. 40; 363-369.
3. Cina, S. J., Lancaster-Weiss, K. J., Lecksell, K. and Epstein, J. I. (2001) Correlation of Ki-67 and p53 with the new World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia. Arch. Pathol. Lab. Med. 125; 646-651.
4. Eble, J. N., Sauter, G., Epstein, J. I. and Sesterhenn, I. A. (2004) World-Health-Organization Tumours of the Urinary System and Male Genital Organs. ed. by S. L. Johansson, C. Busch and V. E. Reuter, IARC Press, Lyon, pp. 115-118.
5. Florl, A. R., Franke, K. H., Niederacher, D., Gerharz, C. D., Seifert, H. H. and Schulz, W. A. (2000) DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. Lab. Invest. 80; 1513-1522.
6. Florl, A. R. and Schulz, W. A. (2008) Chromosomal instability in bladder cancer. Arch. Toxicol. 82; 173-182.
7. Halling, K. C., King, W., Sokolova, I. A., Meyer, R. G., Burkhardt, H. M., Halling, A. C., Cheville, J. C., Sebo, T. J., Ramakumar, S., Stewart, C. S., Pankratz, S., O'Kane, D. J., Seelig, S. A., Lieber, M. M. and Jenkins, R. B. (2000) A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J. Urol. 164; 1768-1775.
8. Halling, K. C. and Kipp, B. R. (2008) Bladder cancer detection using FISH (UroVysion assay). Adv. Anat. Pathol. 15; 279-286.
9. Han, J., Chang, H., Giricz, O., Lee, G. Y., Baehner, F. L., Gray, J. W., Bissell, M. J., Kenny, P. A. and Parvin, B. (2010) Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture. PLoS Comput. Biol. 6; e1000684 (1-12).
10. Kim, W. J. and Bae, S. C. (2008) Molecular biomarkers in urothelial bladder cancer. Cancer Sci. 99; 646-652.
11. King, M. C., Drivas, T. G. and Blobel, G. (2008) A network of nuclear envelope membrane proteins linking centromeres to microtubules. Cell 134; 427-438.
12. Kondo, T., Nakazawa, T., Murata, S., Kurebayashi, J., Ezzat, S., Asa, S. L. and Katoh, R. (2007) Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum. Pathol. 38; 1810-1818.
13. Krause, F. S., Feil, G., Zumbragel, A. and Bichler, K. H. (2000) Molecular genetic methods in the diagnosis of invasive bladder cancer. Anticancer Res. 20; 5015-5021.
14. Lindgren, D., Frigyesi, A., Gudjonsson, S., Sjodahl, G., Hallden, C., Chebil, G., Veerla, S., Ryden, T., Mansson, W., Liedberg, F. and Hoglund, M. (2010) Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 70; 3463-3472.
15. Lopez-Beltran, A. (2008) Bladder cancer: clinical and pathological profile. Scand. J. Urol. Nephrol. Suppl. 95-109.
16. Mallofre, C., Castillo, M., Morente, V. and Sole, M. (2003) Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod. Pathol. 16; 187-191.
17. Ministry of Health, L.a.W. (2006) Vital Statistics of Japan, ed. By Ministry of Health, L.a.W., Tokyo, pp. 294-299.
18. Mitra, A. P., Datar, R. H. and Cote, R. J. (2006) Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J. Clin. Oncol. 24; 5552-5564.
19. Mitra, A. P., Bartsch, C. C. and Cote, R. J. (2009) Strategies for molecular expression profiling in bladder cancer. Cancer Metastasis Rev. 28; 317-326.
20. Murata, S., Mochizuki, K., Nakazawa, T., Kondo, T., Nakamura, N., Yamashita, H., Urata, Y., Ashihara, T. and Katoh, R. (2002) Detection of underlying characteristics of nuclear chromatin patterns of thyroid tumor cells using texture and factor analyses. Cytometry 49; 91-95.
21. Murata, S., Mochizuki, K., Nakazawa, T., Kondo, T., Nakamura, N., Yamashita, H., Urata, Y., Ashihara, T. and Katoh, R. (2003) Morphological abstraction of thyroid tumor cell nuclei using morphometry with factor analysis. Microsc. Res. Tech. 61; 457-462.
22. Murata, S., Kishikawa, T., Isojima, Y., Tsuchihashi, Y. and Katoh, R. (2004) Unusual cytologic findings in low grade papillary transitional cell carcinoma. Acta Cytol. 48; 492-496.
23. Murata, S., Nakazawa, T., Ohno, N., Terada, N., Iwashina, M., Mochizuki, K., Kondo, T., Nakamura, N., Yamane, T., Iwasa, S., Ohno, S. and Katoh, R. (2007) Conservation and alteration of chromosome territory arrangements in thyroid carcinoma cell nuclei. Thyroid 17; 489-496.
24. Murata, S., Iseki, M., Kinjo, M., Matsuzaki, O., Moriuchi, A., Ohtani, H., Sakurai, T., Satake, T. and Tsuzuki, T. (2010) Molecular and immunohistologic analyses cannot reliably solve diagnostic variation of flat intraepithelial lesions of the urinary bladder. Am. J. Clin. Pathol. 134; 862-872.
25. Murphy, W. M., Grignon, D. J. and Perlman, E. J. (2004) Tumors of the Urinary Bladder. In "AFIP Atlas of Tumor Pathology series 4. Tumors of the Kidney, Bladder, and Related Urinary Structures", ed. by W. M. Murphy, D. J. Grignon and E. J. Perlman, AFIP, Washington DC, pp. 255-275.
26. Nakazawa, K., Murata, S., Yuminamochi, T., Ishii, Y., Ohno, S., Nakazawa, T., Kondo, T. and Katoh, R. (2009) p16(INK4a) expression analysis as an ancillary tool for cytologic diagnosis of urothelial carcinoma. Am. J. Clin. Pathol. 132; 776-784.
27. Nakazawa, T., Murata, S., Kondo, T., Niu, D., Mochizuki, K., Kawasaki, T., Yamane, T., Nakamura, N. and Katoh, R. (2009) RET/PTC rearrangements arising from a small population of papillary thyroid carcinoma cells, possible candidate for passenger mutation. Virchows Arch. 455; 35-41.
28. Niu, D., Murata, S., Kondo, T., Nakazawa, T., Kawasaki, T., Ma, D., Yamane, T., Nakamura, N. and Katoh, R. (2009) Involvement of centrosomes in nuclear irregularity of thyroid carcinoma cells. Virchows Arch. 455; 149-157.
29. Ooi, A. (2001) Oncogene amplification detection by fluorescence in situ hybridization (FISH). Acta Histochem. Cytochem. 34; 391-397.
30. Parkin, D. M. (2008) The global burden of urinary bladder cancer. Scand. J. Urol. Nephrol. Suppl. 12-20.
31. Pollard, C., Smith, S. C. and Theodorescu, D. (2010) Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev. Mol. Med. 12; e10 (1-22).
32. Pothos, A., Plastira, K., Plastiras, A., Vlachodimitropoulos, D., Goutas, N. and Angelopoulou, R. (2008) Comparison of chromogenic in situ hybridisation with fluorescence in situ hybridisation and immunohistochemistry for the assessment of her-2/neu oncogene in archival material of breast carcinoma. Acta Histochem. Cytochem. 41; 59-64.
33. Raica, M., Zylis, D. and Cimpean, A. M. (2005) Cytokeratin 20, 34betaE12 and overexpression of HER-2/neu in urine cytology as predictors of recurrences in superficial urothelial carcinoma. Rom. J. Morphol. Embryol. 46; 11-15.
34. Salpingidou, G., Smertenko, A., Hausmanowa-Petrucewicz, I., Hussey, P. J. and Hutchison, C. J. (2007) A novel role for the nuclear membrane protein emerin in association of the centrosome to the outer nuclear membrane. J. Cell Biol. 178; 897-904.
35. Schulz, W. A. (2006) Understanding urothelial carcinoma through cancer pathways. Int. J. Cancer 119; 1513-1518.
36. Sharma, S., Ksheersagar, P. and Sharma, P. (2009) Diagnosis and treatment of bladder cancer. Am. Fam. Physician 80; 717-723.
37. Smith, G. D. and Bentz, J. S. (2010) "FISHing" to detect urinary and other cancers: validation of an imaging system to aid in interpretation. Cancer Cytopathol. 118; 56-64.
38. Sobin, L. H., Gospodarowicz, M. K. and Wittekind, C. (2009) Urinary Bladder. In "TNM Classification of Malignant Tumours. 7th ed.", ed. by M. K. Gospodarowicz, Wiley-Blackwell, London, pp. 262-265.
39. Sokolova, I. A., Halling, K. C., Jenkins, R. B., Burkhardt, H. M., Meyer, R. G., Seelig, S. A. and King, W. (2000) The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J. Mol. Diagn. 2; 116-123.
40. Song, M. J., Lee, H. M. and Kim, S. H. (2010) Clinical usefulness of fluorescence in situ hybridization for diagnosis and surveillance of bladder cancer. Cancer Genet. Cytogenet. 198; 144-150.
41. Sung, M. T., Zhang, S., Lopez-Beltran, A., Montironi, R., Wang, M., Davidson, D. D., Koch, M. O., Cain, M. P., Rink, R. C. and Cheng, L. (2009) Urothelial carcinoma following augmentation cystoplasty: an aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations. Histopathology 55; 161-173.
42. Tomlinson, D. C., Baldo, O., Harnden, P. and Knowles, M. A. (2007) FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol. 213; 91-98.
43. van der Kwast, T. H. and Bapat, B. (2009) Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling. Curr. Opin. Urol. 19; 516-521.
44. Varma, M., Morgan, M., Amin, M. B., Wozniak, S. and Jasani, B. (2004) High-molecular-weight cytokeratin antibody (clone 34betaE12) as a urothelial marker: a note of caution. Histopathology 44; 189-190.
45. Yurakh, A. O., Ramos, D., Calabuig-Farinas, S., Lopez-Guerrero, J. A., Rubio, J., Solsona, E., Romanenko, A. M., Vozianov, A. F., Pellin, A. and Llombart-Bosch, A. (2006) Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur. Urol. 50; 506-515.